AI Echocardiographic Screening of Cardiac Amyloidosis

Launched by CEDARS-SINAI MEDICAL CENTER · Oct 28, 2024

Keywords

ClinConnect Summary

This study tests a new AI tool called EchoNet-LVH that reviews heart ultrasound images (echocardiograms) to flag people who might have cardiac amyloidosis (CA), a rare but serious heart condition. About 500 people will be enrolled from roughly 100,000 echocardiograms across four medical centers. To join, you must be 22 or older, have an echocardiogram that EchoNet-LVH marks as suspicious for CA, and be willing to consent. People whose echo isn’t flagged or who don’t want to participate aren’t invited.

If you are flagged and consent, your case will be reviewed by cardiac amyloidosis experts and you may be asked to have additional testing or evaluation. The study mainly looks at how accurate this AI screening is at identifying CA (within 1 year) and other related steps, such as how quickly a diagnosis is made, how many people receive CA treatment, and health outcomes like hospitalizations. It’s a single-group diagnostic study (no comparison group) and uses an investigational AI tool at several U.S. centers, led by Cedars-Sinai with collaborating sites. The trial began in 2024 and is expected to continue through 2026.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients receiving an echocardiogram that is determined to be suspicious by EchoNet-LVH
• Exclusion Criteria:
• • Patients that decline consent
• • Patients receiving an echocardiogram that is determined to be not suspicious by EchoNet-LVH